Quanterix Corporation (QTRX)
NASDAQ: QTRX · Real-Time Price · USD
4.760
+0.180 (3.93%)
At close: Aug 12, 2025, 4:00 PM
4.770
+0.010 (0.21%)
Pre-market: Aug 13, 2025, 4:16 AM EDT
Quanterix Revenue
Quanterix had revenue of $24.48M in the quarter ending June 30, 2025, a decrease of -28.81%. This brings the company's revenue in the last twelve months to $125.78M, down -2.74% year-over-year. In the year 2024, Quanterix had annual revenue of $137.42M with 12.30% growth.
Revenue (ttm)
$125.78M
Revenue Growth
-2.74%
P/S Ratio
1.46
Revenue / Employee
$267,057
Employees
471
Market Cap
221.18M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 137.42M | 15.05M | 12.30% |
Dec 31, 2023 | 122.37M | 16.85M | 15.96% |
Dec 31, 2022 | 105.52M | -5.03M | -4.55% |
Dec 31, 2021 | 110.56M | 24.18M | 27.99% |
Dec 31, 2020 | 86.38M | 29.64M | 52.25% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
QTRX News
- 1 day ago - Quanterix to Present at the Canaccord Genuity 45th Annual Growth Conference - Business Wire
- 4 days ago - Quanterix Corporation (QTRX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 5 days ago - Quanterix Releases Financial Results for the Second Quarter of 2025 - Business Wire
- 8 days ago - Quanterix To Report Second Quarter 2025 Financial Results on August 7, 2025 - Business Wire
- 8 days ago - Quanterix Announces Cooperation Agreement with Kent Lake Capital - Business Wire
- 15 days ago - Quanterix Launches Novel p-Tau 205 and p-Tau 212 Assays to Advance Alzheimer's Research at AAIC - Business Wire
- 4 weeks ago - Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 5 weeks ago - Quanterix Completes Acquisition of Akoya Biosciences, Creating the First Integrated Platform Capable of Measuring Biomarkers Across the Blood and Tissue Continuum - Business Wire